The pros and cons of plasticity

The brain is influenced by external events

Prof Tomas Paus (University of Toronto, Canada) described, at EPA 2016, adolescence as a dynamic period of brain development - and a time of emerging risk.

‘If the brain was so simple that we could understand it, we would be so simple that we couldn’t.’ - Emerson Pugh

There is interplay between genes and the environment. Prof Paus described the two-hit hypothesis of schizophrenia. Having genetic traits associated with schizophrenia - first hit - plus cannabis use before the age of 16 - second hit - impacts brain structure. Grey matter thickness is reduced. These brain changes may have functional consequences.

ECT and brain plasticity

Prof Bogdan Draganski (Université de Lausanne, Switzerland) demonstrated brain plasticity in response to electroconvulsive therapy (ECT). ECT causes volume increase in the hippocampus. But when using a more basic form of MRI (T1-weighted) to measure these brain changes, there is no straightforward neurobiological interpretation. Moving forwards, novel structural MRI based on biophysical models will allow more valuable neurobiological interpretation of structural brain changes.

Dynamic brain changes

Prof Tomas Hajek (Dalhousie University, Canada) noted that the impact of neuroimaging research on clinical psychiatry has been small so far.

The concept of brain changes is shifting. The idea that mental illness is an expression of a brain lesion may be too simple. Referring to bipolar disorder, Prof Hajek proposed a dynamic model based on illness-related plasticity. Brain changes in mental illness represent an interplay between opposing effects of illness burden and compensatory processes.

Brain changes as diagnostic markers

Primary abnormalities - genetically determined brain changes that increase disease vulnerability - can aid in early identification and diagnosis. But after disease onset, secondary abnormalities - what the patient has gone through - can’t be used for diagnosis. These factors include comorbid conditions, illness duration and treatment. So brain-change markers need to be identified early.

Genetic high-risk trials could be used to study primary abnormalities as diagnostic markers. These include young relatives of patients with bipolar disorder. 

Country selection
We are registering that you are located in Brazil - if that's correct then please continue to Progress in Mind Brazil
Stai abbandonando il sito Progress in Mind
Le informazioni contenute nel nuovo sito prescelto possono non essere conformi al D.Ivo 219/06 che regola la pubblicità dei medicinali per uso umano e le opinioni espresse non riflettono necessariamente le posizioni dell’azienda, non sono da essa avvallate.
ACCESSO RISERVATO A OPERATORI SANITARI AUTORIZZATI
Per accedere alla pagina si prega di registrarsi o, in caso sia già stato fatto, di autenticarsi. La pagina per la quale sta richiedendo l'accesso ospita materiale formativo comunque attinente all'impiego di medicinali prodotti o commercializzati da Lundbeck. Con riferimento al Decreto Legislativo n.219 del 24 aprile 2006 e s.m.i., art. 119, art. 121 comma 1 e art. 124 commi 4 e 8, Lundbeck limita l'accesso ai contenuti presenti nella pagina PIM Academy a medici specialisti e farmacisti ospedalieri.
Ciao
Per favore, conferma la tua email
Ti abbiamo appena inviato un'e-mail con un link di conferma.
Prima di poter ottenere l'accesso completo, devi confermare la tua email.
Le informazioni su questo sito sono destinate esclusivamente ai professionisti della salute.
Congress
Register for access to Progress in Mind in your country